Inclusion Criteria:

- Confirmed diagnosis of intrahepatic carcinoma. The histopathology confirmation
criterion may be waived in patients with a radiographically identifiable liver mass,
known laboratory or clinical risk factors for cancer or elevated tumor markers such
as AFP (clinical diagnosis).

- The cancer must be unresectable.

- ECOG Performance Status Score 0-2

- Age greater than or equal to 18

- Able to comprehend and provide written informed consent in accordance with
institutional and federal guidelines.

Exclusion Criteria:

- Any pre-treatment lab findings within 15 days of treatment demonstrating: absolute
granulocyte count less than or equal to 1,500/ul, platelet count less than or equal
to 45,000/ul, serum creatinine greater than or equal to 3.0 mg/dl, serum bilirubin
greater than or equal to 4.0 mg/dl

- Any of the following contraindications to angiography and selective visceral
catheterization: history of severe allergy or intolerance to any contrast media,
narcotics, sedatives, or atropine; bleeding diathesis, not correctable by usual forms
of therapy; severe peripheral vascular disease that would preclude catheterization

- Portal hypertension with portal venous shunt away from the liver

- Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of
radiation to the lungs on either 1) first TheraSphere administration or 2) cumulative
delivery of radiation to the lungs > 30Gy over multiple treatments.

- Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
application of established angiographic techniques to stop such flow.

- Significant extrahepatic disease representing an imminent life-threatening outcome

- Severe liver dysfunction or pulmonary insufficiency

- Active uncontrolled infection

- Significant underlying medical or psychiatric illness.

- Pregnant women may not participate.